Register your office to receive a $50 credit towards your first case.
China’s plasma biomarker sector is gaining attention as Alzheimer’s disease research moves toward earlier, less invasive assessment. The World Health Organization reports that more than 55 million people live with dementia worldwide, with nearly 10 million new cases each year. This growing burden is increasing demand for reliable Ad Plasma Biomarkers, especially plasma p-tau217, p-tau181, amyloid-beta 42/40, neurofilament light, and GFAP.
Chinese suppliers now support hospitals, CROs, universities, and pharmaceutical trials with ELISA kits, chemiluminescent platforms, and ultrasensitive digital immunoassays. The 2024 Alzheimer’s Association Facts and Figures report highlights rapid progress in blood-based biomarkers, while recent NIA-AA research frameworks emphasize biological evidence over symptoms alone. These developments make analytical sensitivity, clinical validation, and sample stability central purchasing criteria.
Quality differences remain significant. A polished product page is not enough. Buyers should examine ISO 13485 certification, NMPA status where applicable, lot-to-lot precision, matrix validation, reference materials, and peer-reviewed performance data. Suppliers with documented limits of detection and blinded clinical testing deserve closer consideration. Some companies provide strong research-use-only products but limited evidence for routine clinical use. That distinction matters.
There is no permanent “top supplier” ranking. Market visibility, assay quality, regulatory readiness, and technical support can change quickly. This guide therefore evaluates Chinese providers through practical evidence, not promotional claims. It also recognizes an important limitation: published head-to-head comparisons remain incomplete. Careful due diligence is still essential.
WHO estimates that more than 55 million people live with dementia worldwide. Over 60% live in low- and middle-income countries, with nearly 10 million new cases each year. Alzheimer’s disease contributes roughly 60–70% of dementia cases, making scalable blood testing increasingly important. Plasma biomarkers may help identify pathological changes earlier, but they do not replace clinical assessment.
For China-based research and diagnostic procurement, suppliers should demonstrate validated measurements for p-tau217, p-tau181, Aβ42/40, GFAP, and NfL. The 2024 Alzheimer’s Association diagnostic criteria recognize blood-based biomarkers as promising tools, especially when they show strong agreement with amyloid or tau reference methods. Still, performance varies between platforms. Sample handling, antibody design, calibration, and population differences can change results.
The strongest evidence comes from independent cohorts, transparent sensitivity data, and published comparison studies. A supplier should report limits of detection, precision, interference testing, and results across age groups. China’s large and diverse population offers valuable validation opportunities. Yet a single hospital cohort may not represent every region. That limitation deserves attention. I would also question unusually high accuracy claims without external validation. WHO’s disease burden is vast, while plasma testing remains an evolving clinical technology. Clear reporting matters more than impressive marketing language.
